Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
The Latest News
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Sep 25, 2023
Biogen Appoints Jane Grogan as Head of Research
Sep 06, 2023
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Aug 04, 2023
Biogen to Acquire Reata Pharmaceuticals
Jul 28, 2023
Biogen Reports Second Quarter 2023 Results
Jul 25, 2023